Pomegra
bit.bio raised a $25M Series D on November 4, 2026, less than a year after a $50M Series C, to expand its catalogue of lab-grown human cell models for drug discovery.
Key Takeaways
- bit.bio closed a $25M Series D on November 4, 2026; no lead investor or valuation was disclosed.
- Existing investor M&G Investments and Abcam founder Jonathan Milner took part.
- Paid vial volumes are up 76% year to date, and the ioCells range spans more than 50 cell types.
Lead
bit.bio, the Cambridge, UK, human cell programming company, closed a $25M Series D on November 4, 2026. The money will go toward adding human cell types to its portfolio and widening access for pharmaceutical, biotechnology and academic customers. The round follows a $50M Series C from January 2026, which M&G's Crossover team led. At least $75M has therefore arrived in 2026 alone.
The company disclosed neither a lead investor nor a valuation. Participants named in the announcement are M&G Investments, an existing backer, and Dr Jonathan Milner, founder and former CEO of life-science reagents supplier Abcam.
What Does bit.bio Actually Sell?
bit.bio sells ready-to-use human cells grown from stem cells, which researchers use in place of animal models or donor-derived tissue. Its opti-ox platform converts stem cells into a defined cell type through programmed gene expression. The aim is a consistent product from batch to batch.
The commercial line is called ioCells, and it now covers more than 50 cell types, including heart, liver and central nervous system models. Customers use them in disease research, functional genomics, drug discovery and toxicology testing. Batch consistency is the selling point, because donor-derived cells vary and are often in short supply.
How Strong Is Demand for bit.bio's Cell Models?
Demand is growing quickly, by the company's own figures. Paid vial volumes rose 76% year to date in 2026. Orders climbed 34%, the active customer base grew 40%, and academic customers rose 63%.
Those numbers need a caveat. They are growth rates with no base disclosed, so they say nothing about absolute revenue, which bit.bio has not published. A 76% rise from a small number of vials is a different story from the same rise off a large one. Still, vial volume outpacing order count suggests existing customers are buying more per order.
Why Raise a Series D So Soon After the Series C?
Two rounds inside roughly ten months point to a company adding capital as demand arrives, rather than waiting to finish one funding cycle before starting the next. The smaller $25M cheque, with an insider and a single individual named, reads as a top-up and not a repricing event. Without a disclosed valuation, outsiders cannot tell whether the round was priced up, flat or down against the Series C.
The use of funds is narrow. Coverage of the round says no additional production infrastructure is needed, so the spending goes to new cell types and customer growth. That is a cheaper plan than building plant, and it fits a business whose manufacturing is already running.
Leadership has also changed. Dr Emma Pepperell, who previously led the commercial team, became CEO in June 2026. A commercially minded chief executive raising a growth round on sales metrics is consistent with that background.
What Is Driving the Market for Human Cell Models?
Two forces sit behind the pitch, and both come from the company itself. Pepperell said the industry is reaching an inflection point: AI is speeding up how fast new medicines can be discovered, while the shift toward alternatives to animal testing is creating demand for models that better reflect human biology.
The argument has a logic. Faster computational candidate generation moves the bottleneck to experimental validation, and validation needs reliable human cells in volume. Regulatory pressure to reduce animal testing pushes in the same direction. The counterpoint is that many drug developers already buy primary cells, organoids and competing stem cell-derived products, so bit.bio must show that standardisation justifies switching.
Milner framed the opportunity through his own history. He said Abcam showed how a focused product offering can grow into a global business by becoming indispensable to researchers. That comparison sets a high bar. Abcam built its position on catalogue breadth and distribution reach over many years.
What Comes Next for bit.bio?
The next milestones are measurable. Investors will look for new ioCells releases, a disclosed revenue figure, and evidence that academic uptake converts into pharmaceutical contracts, which typically pay more. A valuation, if it emerges in a later filing, would show how the market priced the company against its Series C.
Risks are plain. Growth percentages without a base invite scepticism, competitors sell overlapping products, and a catalogue business needs scale before margins improve. Regulatory movement on animal testing could help demand, but timelines for such changes tend to run slower than company forecasts.
Outlook
bit.bio has now raised $75M across two rounds in 2026, with a new CEO, a 50-plus cell type catalogue and double-digit growth in customers and orders. The Series D gives it room to widen the portfolio without building new manufacturing. The open questions are valuation, revenue and whether pharma buyers adopt programmed cells as a standard input.
